Strategies of extensively drug-resistant TB risk management for health workers and other care givers

Expert Review of Respiratory Medicine

Volumn 2, Issue 1, 2008, Pages 47-54

  Chiang, Chen Yuan ^a   Enarson, Donald A ^a   Fujiwara, Paula I ^a,b   van Deun, Armand ^a   Lee, Jen Jyh ^c  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Administrative controls; Environmental controls; MDR TB; Personal protection; Prevention; Rapid susceptibility testing; Tuberculosis; XDR TB

Indexed keywords

AMINOSALICYLIC ACID; BCG VACCINE; CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

AGE; ARTICLE; BACTERIAL TRANSMISSION; BCG VACCINATION; BIRTHPLACE; CAREGIVER; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DEVELOPING COUNTRY; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; ENVIRONMENTAL PROTECTION; GENOTYPE; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; MYCOBACTERIUM TUBERCULOSIS; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; PATIENT CARE; PHENOTYPE; PREVALENCE; PRISON; PROTECTIVE EQUIPMENT; RISK REDUCTION; ROOM VENTILATION; SPUTUM ANALYSIS; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 47649089814     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2.1.47     Document Type: Article

References (44)

1. Goble M, Iseman MD, Madsen LA. Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N. Engl. J. Med. 328, 527-532 (1993).
2. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. Morb. Mortal. Wkly. Rep. 55, 301-305 (2006).
3. Yew WW, Chan CK, Chau CH et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/ levofloxacin-containing regimens. Chest 117, 744-751 (2000).
4. World Health Organization. Report of the meeting of the WHO global task force on XDR-TB. Geneva, Switzerland, 9-10 October 2006. WHO/HTM//TB/ 2006.375,1-23 (2006).
5. Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis in a rural area of South Africa. Lancet 368, 1575-1580 (2006).
6. Frieden TR, Fine Sherman L, Maw KL et al. A multi-institutional outbreak of highly drug-resistant tuberculosis. JAMA 276, 1229-1235 (1996).
7. Kochi A, Vareldzis B, StybloK. Multidrug-resistant tuberculosis and its control. Res. Microbiol. 144, 104-110 (1993).
8. Zhang LX, Kan GQ, Tu DH, Li JS, Liu XX. Trend of initial drug resistance of tubercle bacilli isolated from new patients with pulmonary tuberculosis and its correlation with the tuberculosis programme in Beijing. Tuber. Lung Dis. 76, 100-103 (1995).
9. Kim HJ, Hong YP, Kim SJ, Lew WJ, Lee EG. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int. J. Tuberc. Lung Dis. 5, 1129-1136 (2001).
10. Flament-Saillour M, Robert J, Jarlier V, Grosser J. Outcome of multi-drug-resistant tuberculosis in France. A nationwide case-control study. Am. J. Respir. Crit. Care Med. 160, 587-593 (1999).
11. Schaaf HS, Botha P, Gie RP et al. The 5-year outcome of multidrug resistant tuberculosis patients in the Cape Province of South Africa. Trop. Med. Intern. Health 1, 718-722 (1996).
12. Iseman MD, Madsen L, Goble M, Pomerantz M. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 141, 623-625 (1990).
13. Chiang C-Y, Yu M-C, Bai K-J, Lin T-P, Lee Y-C. Pulmonary resection in the treatment of patients with pulmonary multidrug-resistant tuberculosis in Taiwan. Int. J. Tuberc. Lung Dis. 5, 272-277 (2001).
14. Chan ED, Laurel V, Strand MJ et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Rapir. Crit. Care Med. 169, 1103-1109 (2004).
15. Chiang C-Y, Enarson DA, Yu M-C et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur. Respir. J. 28, 980-985 (2006).
16. Törün T, Tahaoglu K, Özmen I et al. The role of surgery and fluoroquinolones in the treatment of multidrug-reistant tuberculosis. Int. J. Tuberc. Lung Dis. 11, 979-985 (2007).
17. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am. Rev Respir. Dis. 133, 423-430 (1986).
18. Espinal MA, Kim SJ, Suarez PG et al. Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries. JAMA 283, 2537-2545 (2000).
19. Bai K-J, Yu M-C, Chiang C-Y, Chiang I-H, Lin T-P, Luh K-T, Short-course chemotherapy for isoniazid-resistant pulmonary tuberculosis. J. Former. Med. Assoc. 97, 278-282 (1998).
20. Tahaoglu K, Törün T, Sevim T et al. The treatment of multidrug-resistant tuberculosis in Turkey. N. Engl. J. Med. 345, 170-174 (2001).
21. Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/ KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 45,1409-14 (2007).
22. Grimaldo ER, Tupasi TE, Rivera AB et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int. J. Tuberc. Lung Dis. 5, 546-550 (2001).
23. Wang JY, Hsueh PR, Jan IS et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 61, 903-908 (2006).
24. Menzies D, Joshi R, Pai M. Risk of tuberculosis infection and disease associated with work in health care settings. Int. J. Tuberc. Lung Dis. 11, 593-605 (2007).
25. Abrahão RMCM, Nogueira PA, Malucelli MIC. Tuberculosis in county jail prisoners in the western sector of the city of Sio Paulo, Brazil. Int. J. Tuberc. Lung Dis. 10, 203-208 (2006).
26. Aerts A, Habouzit M, Mschiladze M et al. Pulmonary tuberculosis in prisons in the ex-USSR state Georgia: results of a nation-wide prevalence survey among sentenced inmates. Int. J. Tuberc. Lung Dis. 4, 1104-1110 (2000).
27. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City - turning the tide. N. Engl. J. Med. 333, 229-233 (1995).
28. Portugal I, Covas MJ, Brum L et al. Outbreak of multiple drug-resistant tuberculosis in Lisbon: detection by restriction fragment length polymorphism analysis. Int. J. Tuberc. Lung Dis. 3, 207-213 (1999).
29. Valway SE, Richards SB, Kovacovich J, Greifinger RB, Crawford JT, Dooley SW. Outbreak of multi-drug-resistant tuberculosis in a New York State prison, 1991. Am. J. Epidemiol. 140, 113-122 (1994).
30. McLaughlin SI, Spradling P, Drociuk D, Ridzon R, Pozsik CJ, Onorato I. Extensive transmission of Mycobacterium tuberculosis among congregated, HIV-infected prison inmates in South Carolina, United States. Int. J. Tuberc. Lung Dis. 7, 665-672 (2003).
31. International Union Against Tuberculosis and Lung Disease, World Health Organization. Control of tuberculosis transmission in health care settings. A joint statement of the International Union Against Tuberculosis and Lung Disease (IUATLD) and the Tuberculosis Programme of the World Health Organization (WHO). Tuber. Lung Dis. 75, 94-95 (1994).
32. World Health Organization. Guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. World Health Organization Document WHO/CDC/TB/99.269, 1-51 (1999).
33. World Health Organization. Guidelines for the control of tuberculosis in prisons. World Health Organization Document WHO/TB/98.250, 1-87 (1998).
34. World Health Organization. Tuberculosis control in prisons. A manual for programme managers. World Health Organization Document WHO/CDS/TB/ 2001.281, 1-176 (2001).
35. Centers for Disease Control and Prevention. Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC. Endorsed by the Advisory Council for the Elimination of Tuberculosis, the National Commission on Correctional Health Care, and the American Correctional Association. Morb. Mortal. Wkly Rep. 55(No. RR-9), 1-54 (2006).
36. Rieder HL. Epidemiologic basis of tuberculosis control. In: International Union Against Tuberculosis and Lung Disease (1st Edition). 1-162. International Union Against Tuberculosis and Lung Disease. Paris, France (1999).
37. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur. Respir. J. 125, 564-569 (2005).
38. Palomino JC. Newer diagnostics for tuberculosis and multi-drug resistant tuberculosis. Curr. Opin. Pulm. Med. 12, 172-178 (2006).
39. Morgan M, Kalantri S, Flores L, Pai M. A commerical line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect. Dis. 5(62), 1-9 (2005).
40. Umubyeyi AN, Martin A, Zissis G, Struelens M, Karita E, Portaels F. Evaluation of the resazurin microtiter assay for rapid detection of ofloxacin resistance in M. tuberculosis. Int. J. Tuberc. Lung Dis. 10, 808-811 (2006).
41. Moore DAJ, Evans CAW, Gilman RH et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N. Engl. J. Med. 355, 1539-1550 (2007).
42. Traore H, Ogwang S, Mallard K et al. Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda. Ann. Clin. Microbiol. Antimicrob. 6, 1 (2007).
43. World Health Organization. Guidelines of the programmatic management of drug-resistant tuberculosis. World Health Organization Document WHO/HTM/ TB/2006.361, 26 (2006).
44. Basu S, Andrews JR, Poolman EM et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modeling study. Lancet 370, 1500-1507 (2007).